Athersys (NASDAQ:ATHX) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Athersys (NASDAQ:ATHXFree Report) in a research note released on Monday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Athersys Price Performance

ATHX opened at $0.00 on Monday. The firm has a market cap of $203,672.70, a P/E ratio of 0.00 and a beta of -0.90. Athersys has a twelve month low of $0.01 and a twelve month high of $1.99.

About Athersys

(Get Free Report)

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

See Also

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.